Page 118 - 中国全科医学2022-17
P. 118
http://www.chinagp.net E-mail:zgqkyx@chinagp.net.cn ·2163·
Rheum Dis,2017,76(8):1340-1347. DOI:10.1136/annrheu 2118. DOI:10.3389/fimmu.2018.02118.
mdis-2016-210322. [18]WALLACE D J,FURIE R A,TANAKA Y,et al. Baricitinib for
[5]VAN DER HEIJDE D,BARALIAKOS X,GENSLER L S, systemic lupus erythematosus:a double-blind,randomised,
et al. Efficacy and safety of filgotinib,a selective Janus kinase placebo-controlled,phase 2 trial[J]. Lancet,2018,392
1 inhibitor,in patients with active ankylosing spondylitis (10143):222-231. DOI:10.1016/S0140-6736(18)31363-1.
(TORTUGA):results from a randomised,placebo-controlled, [19]LI Y P,HIGGS R E,HOFFMAN R W,et al. A Bayesian gene
phase 2 trial[J]. Lancet,2018,392(10162):2378-2387. network reveals insight into the JAK-STAT pathway in systemic
DOI:10.1016/S0140-6736(18)32463-2. lupus erythematosus[J]. PLoS One,2019,14(12):
[6]VAN DER HEIJDE D,SONG I H,PANGAN A L,et al. Efficacy e0225651. DOI:10.1371/journal.pone.0225651.
and safety of upadacitinib in patients with active ankylosing spondylitis [20]SHAO W H,SHU D H,ZHEN Y X,et al. Prion-like aggregation
(SELECT-AXIS 1):a multicentre,randomised,double-blind, of mitochondrial antiviral signaling protein in lupus patients
placebo-controlled,phase 2/3 trial[J]. Lancet,2019,394 is associated with increased levels of type Ⅰ interferon[J].
(10214):2108-2117. DOI:10.1016/S0140-6736(19)32534-6. Arthritis Rheumatol,2016,68(11):2697-2707. DOI:
[7]O'SHEA J J,SCHWARTZ D M,VILLARINO A V,et al. The 10.1002/art.39733.
JAK-STAT pathway:impact on human disease and therapeutic [21]ALUNNO A,PADJEN I,FANOURIAKIS A,et al. Pathogenic
intervention[J]. Annu Rev Med,2015,66:311-328. DOI: and therapeutic relevance of JAK/STAT signaling in systemic lupus
10.1146/annurev-med-051113-024537. erythematosus:integration of distinct inflammatory pathways and the
[8]OWEN K L,BROCKWELL N K,PARKER B S. JAK-STAT prospect of their inhibition with an oral agent[J]. Cells,2019,8
signaling:a double-edged sword of immune regulation and cancer (8):E898. DOI:10.3390/cells8080898.
progression[J]. Cancers,2019,11(12):2002. DOI: [22]DALBETH N,CHOI H K,JOOSTEN L A B,et al. Gout[J].
10.3390/cancers11122002. Nat Rev Dis Primers,2019,5(1):69. DOI:10.1038/s41572-
[9]HAMMARÉN H M,VIRTANEN A T,RAIVOLA J,et al. The 019-0115-y.
regulation of JAKs in cytokine signaling and its breakdown in [23]SUN Y,ABBONDANTE S,KARMAKAR M,et al. Neutrophil
disease[J]. Cytokine,2019,118:48-63. DOI:10.1016/j. caspase-11 is required for cleavage of caspase-1 and secretion
cyto.2018.03.041. of IL-1β in Aspergillus fumigatus infection[J]. J Immunol,
[10]MALEMUD C J. The role of the JAK/STAT signal pathway in 2018,201(9):2767-2775. DOI:10.4049/jimmunol.1701195.
rheumatoid arthritis[J]. Ther Adv Musculoskelet Dis,2018,10 [24]WINKLER S,RÖSEN-WOLFF A. Caspase-1:an integral
(5/6):117-127. DOI:10.1177/1759720X18776224. regulator of innate immunity[J]. Semin Immunopathol,2015,37
[11]SCHETT G,EMERY P,TANAKA Y,et al. Tapering biologic (4):419-427. DOI:10.1007/s00281-015-0494-4.
and conventional DMARD therapy in rheumatoid arthritis:current [25]TEMMOKU J,FUJITA Y,MATSUOKA N,et al. Uric acid-
evidence and future directions[J]. Ann Rheum Dis,2016,75(8): mediated inflammasome activation in IL-6 primed innate immune
1428-1437. DOI:10.1136/annrheumdis-2016-209201. cells is regulated by baricitinib[J]. Mod Rheumatol,2021,31(1):
[12]YOU H X,XU D,ZHAO J L,et al. JAK inhibitors:prospects 270-275. DOI:10.1080/14397595.2020.1740410.
in connective tissue diseases[J]. Clin Rev Allergy Immunol, [26]FRANCHIMONT N,WERTZ S,MALAISE M. Interleukin-6:an
2020,59(3):334-351. DOI:10.1007/s12016-020-08786-6. osteotropic factor influencing bone formation? [J]. Bone,2005,
[13]ZHANG A,LEE Y C. Mechanisms for joint pain in rheumatoid 37(5):601-606. DOI:10.1016/j.bone.2005.06.002.
arthritis(RA):from cytokines to central sensitization[J]. Curr [27]CHEON Y H,KIM J Y,BAEK J M,et al. WHI-131 promotes
Osteoporos Rep,2018,16(5):603-610. DOI:10.1007/ osteoblast differentiation and prevents osteoclast formation and
s11914-018-0473-5. resorption in mice[J]. J Bone Miner Res,2016,31(2):
[14]BOYDEN S D,HOSSAIN I N,WOHLFAHRT A,et al. 403-415. DOI:10.1002/jbmr.2612.
Non-inflammatory causes of pain in patients with rheumatoid [28]XU L J,ZHANG L X,ZHANG H J,et al. The participation
arthritis[J]. Curr Rheumatol Rep,2016,18(6):30. DOI: of fibroblast growth factor 23(FGF23)in the progression of
10.1007/s11926-016-0581-0. osteoporosis via JAK/STAT pathway[J]. J Cell Biochem,2018,
[15]BARAL P,UDIT S,CHIU I M. Pain and immunity:implications 119(5):3819-3828. DOI:10.1002/jcb.26332.
for host defence[J]. Nat Rev Immunol,2019,19(7):433- [29]DALAGIORGOU G,PIPERI C,ADAMOPOULOS C,et al.
447. DOI:10.1038/s41577-019-0147-2. Mechanosensor polycystin-1 potentiates differentiation of human
[16]TAYLOR P C,KEYSTONE E C,VAN DER HEIJDE D, osteoblastic cells by upregulating Runx2 expression via induction of
et al. Baricitinib versus placebo or adalimumab in rheumatoid JAK2/STAT3 signaling axis[J]. Cell Mol Life Sci,2017,74(5):
arthritis[J]. N Engl J Med,2017,376(7):652-662. DOI: 921-936. DOI:10.1007/s00018-016-2394-8.
10.1056/nejmoa1608345. [30]JETHWA H,BOWNESS P. The interleukin(IL)-23/IL-17
[17]CECCHINATO V,D'AGOSTINO G,RAELI L,et al. Redox- axis in ankylosing spondylitis:new advances and potentials for
mediated mechanisms fuel monocyte responses to CXCL12/HMGB1 treatment[J]. Clin Exp Immunol,2016,183(1):30-36.
in active rheumatoid arthritis[J]. Front Immunol,2018,9: DOI:10.1111/cei.12670.